Sana Biotechnology Inc.'s stock soared over 200% on Wednesday, on track to mark its best day on record, amid trading volumes spiking to 54 times the daily average. The surge followed highly positive ...

Sana Biotechnology (SANA), a clinical-stage biotech company specializing in gene and cell therapies, has recently experienced ...

On Tuesday, Sana Biotechnology Inc (SANA) stock saw a decline, ending the day at $2.92 which represents a decrease of $-0.24 or -7.59% from the prior close of $3.16. The stock opened at $3.17 and ...

Sana Biotechnology Inc (SANA) stock saw a decline, ending the day at $3.49 which represents a decrease of $-0.01 or -0.29% from the prior close of $3.5. The stock opened at $3.41 and touched a low of ...

We recently compiled a list of the 10 Hottest Smid-Cap Stocks So Far In 2025. In this article, we are going to take a look at ...

As researchers push for a type 1 diabetes cure, Sana Biotechnology has provided a nudge forward with new, if limited, ...

Sana Biotechnology's first-in-human study shows UP421 pancreatic islet cells surviving and functioning in type 1 diabetes ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Sana Biotechnology (NASDAQ:SANA) climbed over 200% on Wednesday following a sharp rally in the post-market yesterday in reaction to a Phase 1 readout for its UP421 cell therapy, which, according ...

Since Sana released the data yesterday after market close, the biotech’s stock price has skyrocketed from $1.75 per share to $4.92 as of 10:30 a.m. ET today.

It may be difficult for Sana to protect its technology from the prying eyes of other Pharma and biotech companies, using patents and maintaining a veil of secrecy. For me personally, however ...

Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Sana Biotechnology (SANA – Research Report) yesterday and set a ...